Reported Earnings • Dec 01
Third quarter 2022 earnings released: US$0.004 loss per share (vs US$0.003 loss in 3Q 2021) Third quarter 2022 results: US$0.004 loss per share (further deteriorated from US$0.003 loss in 3Q 2021). Revenue: US$363.1k (up 28% from 3Q 2021). Net loss: US$901.3k (loss widened 31% from 3Q 2021). Over the last 3 years on average, earnings per share has increased by 74% per year but the company’s share price has fallen by 37% per year, which means it is significantly lagging earnings. Board Change • Nov 16
No independent directors Following the recent departure of a director, there are no independent directors on the board. The company's board is composed of: No independent directors. 5 non-independent directors. Director Paul Pellegrini was the last director to join the board, commencing their role in 2022. The company's lack of independent directors is a risk according to the Simply Wall St Risk Model. Announcement • Oct 27
Bhang Inc. Announces Changes to Board of Directors Bhang Inc. announced that Jessica Billingsley and Andrea L. Johnston have resigned from their respective positions as Directors of the Company. The Company is also announced that it has appointed Sara Lee Irwin and Paul Pellegrini to its Board of Directors. Ms. Irwin is a nationally recognized public voice on cannabis and cannabinoids for therapeutic use. With over decades of experience as both an industry consultant and chronic pain patient, Sara has leveraged her personal experience to become a leading representative and liaison working to bridge interests across multiple stakeholder groups, including patients, physicians, researchers, the pharmaceutical industry, investors, institutional brokers, and government. An early advocate of the benefits of the pharmaceutical application of cannabinoids, Ms. Irwin was the Director of Investor Relations at Cannasat Therapeutics between 2004 - 2010, an early-stage cannabinoid pharmaceutical company that, in 2006, became the first publicly traded herbal cannabis company in North America. Ms. Irwin was a founding director of Miraculo Inc., an integrated media, technology and consumer product company in the medical cannabis and CBD industry which was recently acquired by Trees Corporation, a premier Canadian cannabis retailer. Mr. Pellegrini is the Executive Chairman and Founder of Sussex Strategy Group. He brings a track record of proven success in strategic consulting based on direct government experience and his relationship-building expertise. In 1990, as President of HealthWatch, Mr. Pellegrini began providing strategic consulting services to clients in the public and private sectors on a wide variety of business, government relations and public affairs matters. Mr. Pellegrini's expertise in issues management, crisis communications, and stakeholder relations was called upon to serve in a variety of senior roles in federal and provincial ministerial offices. Subsequent to his tenure in the public sector, Mr. Pellegrini founded Sussex in 1998. Mr. Pellegrini currently serves on the Campaign Cabinet for the new Vaughan hospital and sits on the Board of Directors for CHAR Technologies. He is recognized as an active community leader advocating for numerous non-profit and charitable causes. Often interviewed for his insights into current government issues, Mr. Pellegrini has been a political commentator on CP24. 
